Therapeutics

SUVN-502

Overview

Name: SUVN-502
Therapy Type: Small Molecule (timeline)
Target Type: Other Neurotransmitters (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2)
Company: Suven Life Sciences Ltd

Background

Developed by Suven Inc., the Delawa-based subsidiary of Indian company Suven Life Sciences, SUVN-502 is a selective antagonist of the 5-HT6 serotonin receptor. This G protein-coupled receptor is expressed mostly in the brain, where it mediates neurotransmission for functions including cognition and memory. Blocking this receptor increases cholinergic and glutamatergic signaling, and other 5-HT6 receptor antagonists have been reported to improve cognition or are being developed as treatments for Alzheimer's, as well (see Upton et al., 2008RVT-101IdalopirdineDimebon; see Bezprozvanny 2010).

No information about this compound is published in the peer-reviewed literature. Suven scientists reported some preclinical data for it, claiming that it readily enters the brain, increased brain acetylcholine and glutamate levels, and reversed memory deficits in adult rats (Nirogi et al., 2011).

Findings

According to the company's website, Phase 1 studies were conducted in Switzerland in 2008. At the 2009 ICAD conference, Suven scientists presented positive safety and pharmacokinetic data from a single ascending-dose Phase 1 trial conducted in healthy men (Nirogi et al., 2009). 

In September 2015, a Phase 2a proof-of-concept trial began enrolling what is to be 537 patients with probable Alzheimer's disease as diagnosed by the 1984 NINCDS-ADRDA criteria and a MMSE of between 12 and 20. The trial will compare 26 weeks of treatment with a high and a low dose of SUVN-502 to placebo, all given in addition to donepezil. Conducted at 57 sites in the United States, this trial will measure change on the ADAS-cog as primary outcome, and change on the CDR and various clinical and functional scales as secondary outcomes. It is set to run through spring 2017. 

For trials of this compound, see clinicaltrials.gov.

Clinical Trial Timeline

  • Phase 2
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Sponsor Clinical Trial 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Suven Life Sciences Ltd NCT02580305
N=537

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Therapeutics Citations

  1. Intepirdine
  2. Idalopirdine
  3. Dimebon

Paper Citations

  1. . Safety, tolerability and pharmacokinetics of SUVN-502 - A 5-HT6 receptor antagonist, first in human phase-1 Single Ascending Dose (SAD) study. July 2009, Volume 5, Issue 4, Supplement, Page P250
  2. . 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):458-69. PubMed.
  3. . The rise and fall of Dimebon. Drug News Perspect. 2010 Oct;23(8):518-23. PubMed.
  4. . SUVN-502: A potent and selective 5-HT6 antagonist, potential drug for the treatment of Alzheimer's disease. July 2011, Volume 7, Issue 4, Supplement, Page S659

External Citations

  1. clinicaltrials.gov

Further Reading

No Available Further Reading